Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers
January 27, 2026 – Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical – AI-driven IPS score, Tempus, artificial intelligence, biomarkers, immune checkpoint inhibitors, oncology
27 January 2026 — Illinois, US — Tempus AI, Inc, a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that its algorithmic test, Immune Profile Score (IPS), more accurately predicts outcomes for patients receiving immune checkpoint inhibitors (ICIs) than conventional biomarkers, including tumor mutational burden (TMB) and microsatellite instability (MSI), and PD-L1.
IPS is a multimodal biomarker that combines known and novel clinical and immune-related biomarkers from DNA and RNA analysis to predict a patient’s response to ICI-based therapy. The new clinical validation results demonstrate that IPS consistently outperforms conventional biomarkers, highlighting its potential to change the way physicians can identify patients most likely to benefit from immunotherapy. In four independent validation cohorts of pan-cancer metastatic solid organ cancer patients, IPS was shown to be a more accurate predictor of ICI outcomes (HR=0.45) than TMB, MSS, and PD-L1, demonstrating prognostic utility that is independent of those conventional biomarkers.
IPS identified 13% of patients with microsatellite stable colorectal cancer who demonstrated strong real-world overall survival with ICI treatment (HR=0.2), indicating that ICI immunotherapy may be a viable option for a key patient population that might have been overlooked with conventional biomarkers alone. Beyond colorectal cancer, the study’s findings highlight how IPS could expand treatment options for patients with rare cancers. IPS classified 17% of patients with rare metastatic solid tumors as “IPS-High,” despite these patients not falling within a cancer-specific FDA-approved ICI label. The significant difference in median real-world overall survival in “IPS High” versus “IPS-Low” patients (HR=0.26) shows that ICI could be a relevant and potentially life-saving option for patients that might otherwise be missed.
“This study builds on previous findings showing that IPS scoring can identify patients who may have better overall survival with ICI therapy. These results are a significant step forward in the personalization of cancer care, particularly for patients that might be missed by conventional biomarkers,” said Halla Nimeiri, MD, Chief Development Officer at Tempus. “By leveraging a multimodal algorithm, our IPS test provides a more accurate and comprehensive view than traditional, independent biomarkers, empowering physicians to make more confident treatment decisions for their patients while simultaneously moving the field forward in meaningful ways.”
The test is available as an add-on for clinicians ordering Tempus’ xT (DNA) and xR (RNA) assays, helping to manage patients on immunotherapy by utilizing data already collected as part of a patient’s standard sequencing.
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
